Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could replace daily pills for hypertension

NCT ID NCT06857955

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 5 times

Summary

This study tests an experimental drug called QCZ484, given as an injection under the skin every 6 months, for people with mild to moderate high blood pressure. About 385 adults aged 18 to 75 are taking part. The goal is to see if the drug safely lowers blood pressure compared to a placebo over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
QCZ484 (injection)
What this could lead to
If successful, this could lead to a new treatment option for high blood pressure that requires only two injections per year instead of daily pills.
What could go wrong
This is an early Phase 2 trial with only 385 participants. The drug may not lower blood pressure enough or could have side effects. It is not yet proven to work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

396 people

The number who actually took part.

Started

Mar 2025

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed informed consent. 2. Males or females aged 18 to 75 years. 3. Diagnosis of hypertension. 4. Hypertension treatment naive or on maximum 2 anti-HTN medications and able to undergo washout for 4 weeks. 5. Mean sitting SBP ≥140 mmHg measured by OBPM and mean 24 hr SBP ≥130 mmHg and \<160 mmHg measured by ABPM. 6. Participants able to understand and comply with study procedures. Exclusion Criteria: 1. Known history of secondary hypertension. 2. Orthostatic hypotension. 3. Laboratory parameter assessments outside of range at screening. 4. Evidence of hepatic disease. 5. Medical condition, other than hypertension, requiring treatment with RAAS inhibitor. 6. Any history of congestive heart failure. 7. Current or history of intolerance to ACEi and/or ARBs. 8. Clinically significant cardiac arrhythmias, high-grade AV block and third-degree AV block within 6 months prior to screening. 9. Acute myocardial infarction (AMI) or unstable angina, or any percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) within 12 months prior to screening. Any history of ischemic or hemorrhagic stroke or transient ischemic attack any time prior to screening. Other protocol-defined inclusion/exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension

Contacts and locations

Locations

  • AA Medical Research Center

    Flint, Michigan, 48504, United States

  • ALL Medical Research LLC

    Cooper City, Florida, 33024, United States

  • AMR Las Vegas

    Las Vegas, Nevada, 89119, United States

  • Accellacare of Rocky Mount

    Rocky Mount, North Carolina, 27804, United States

  • Accellacare of Salisbury

    Salisbury, North Carolina, 28144, United States

  • Alliance for Multispecialty Research

    Wichita, Kansas, 67207, United States

  • American Research Centers of FL

    Pembroke Pines, Florida, 33027, United States

  • Anderson Medical Research

    Ft. Washington, Maryland, 20744, United States

  • Ascension Saint Agnes Heart Care

    Baltimore, Maryland, 21229, United States

  • Biopharma Informatic

    Katy, Texas, 77479, United States

  • CR Services Acquisition US

    Columbus, Ohio, 43213, United States

  • Capitol Cardiology Associates

    Lanham, Maryland, 20706, United States

  • Cardiology Partners Clinical Research Institute

    Wellington, Florida, 33449, United States

  • Cedar Crosse Research Ct

    Chicago, Illinois, 60607, United States

  • Cen Exel FCR

    Tampa, Florida, 33613, United States

  • Cen Exel RCA

    Hollywood, Florida, 33024, United States

  • CenExel HRI

    Berlin, New Jersey, 08009, United States

  • Centricity Research

    Columbus, Georgia, 31904, United States

  • Centricity Research Suffolk Fam Med

    Suffolk, Virginia, 23435, United States

  • Clin Rsrch Consult a JCCT Company

    Kansas City, Missouri, 64112, United States

  • Clinical Neuroscience Solutions Inc

    Memphis, Tennessee, 38119, United States

  • Clinical Research of Brandon LLC

    Brandon, Florida, 33511, United States

  • Clinical Trials Research Sacramento

    Sacramento, California, 95821-2134, United States

  • Clinical Trials of Texas

    San Antonio, Texas, 78229, United States

  • Conrad Clinical Research

    Edmond, Oklahoma, 73013, United States

  • Dominion Medical Associates

    Richmond, Virginia, 23219, United States

  • Downtown L A Research Center Inc

    Los Angeles, California, 90017, United States

  • Eagle Clinical Research

    Chicago, Illinois, 60621, United States

  • East Coast Institute for Research

    Jacksonville, Florida, 32216, United States

  • Elite Clinical Studies

    Phoenix, Arizona, 85018, United States

  • Encompass Clinical Research

    Spring Valley, California, 91978-1522, United States

  • Entrust Clinical Research

    Miami, Florida, 33176, United States

  • Healthcare Research Network II LLC

    Hazelwood, Missouri, 63042, United States

  • Inpatient Research Clinical LLC

    Miami Lakes, Florida, 33014, United States

  • Javara Research

    Fayetteville, Georgia, 30214, United States

  • Jefferson City Medical Group

    Jefferson City, Missouri, 65109, United States

  • Longwood Research

    Huntsville, Alabama, 35801, United States

  • Manassas Clinical Research Center

    Manassas, Virginia, 20110, United States

  • Monroe Biomedical Research

    Monroe, North Carolina, 28112, United States

  • NICRs Research Center

    Garden Grove, California, 92844, United States

  • National Research Institute

    Hialeah, Florida, 33013, United States

  • North Hills Medical Research Inc

    Bedford, Texas, 76021, United States

  • Novartis Investigative Site

    Suita, Osaka, 5650853, Japan

  • Novartis Investigative Site

    Chuo Ku, Tokyo, 1030027, Japan

  • Novartis Investigative Site

    Chuo Ku, Tokyo, 1040031, Japan

  • Novartis Investigative Site

    Chuo-ku, Tokyo, 1030027, Japan

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo, 1600008, Japan

  • Novartis Investigative Site

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    Singapore, 308433, Singapore

  • Novartis Investigative Site

    Singapore, 519466, Singapore

  • Novartis Investigative Site

    Singapore, 529889, Singapore

  • Oakland Medical Research Center

    Troy, Michigan, 48085, United States

  • Renstar Medical Research

    Ocala, Florida, 34470, United States

  • SEC Clinical Research LLC

    Andalusia, Alabama, 36420, United States

  • Solaris Clinical Research

    Meridian, Idaho, 83646, United States

  • Southern Clin Research Clinic

    Zachary, Louisiana, 70791, United States

  • Sun Research Institute

    San Antonio, Texas, 78205, United States

  • Synergy Group Medical LLC

    Houston, Texas, 77061, United States

  • Synergy Groups Medical LLC

    Missouri City, Texas, 77459, United States

  • Synexus Clinical Research US

    Evansville, Indiana, 47714, United States

  • Synexus Clinical Research US Inc

    Tucson, Arizona, 85741, United States

  • Synexus Clinical Research US Inc

    Richfield, Minnesota, 55432, United States

  • TCV Clinical Studies

    Linwood, Pennsylvania, 19061, United States

  • The Center for Clinical Trials

    Saraland, Alabama, 36571, United States

  • Trinity Health Michigan Heart

    Ypsilanti, Michigan, 48197, United States

  • Valiance Clinical Research

    Huntington Park, California, 90255, United States

  • Velocity Clin Research Sioux City

    Sioux City, Iowa, 51106, United States

  • Velocity Clin at Pioneer Heart Inst

    Lincoln, Nebraska, 68506, United States

  • Velocity Clinical Res Baton Rouge

    Baton Rouge, Louisiana, 70809, United States

  • Velocity Clinical Research

    Savannah, Georgia, 31406, United States

  • Velocity Clinical Research

    Union, South Carolina, 29379, United States

  • Velocity Clinical Research Austin

    Austin, Texas, 78759, United States

  • Velocity Clinical Research Medford

    Medford, Oregon, 97504, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.